GSK Targets Food Allergy Market with $2.2 Billion Acquisition of RAPT Therapeutics

Naarden, Tuesday, 20 January 2026.
GSK’s $2.2 billion acquisition secures a potential best-in-class food allergy treatment offering unique quarterly dosing, strategically bolstering its pipeline against looming patent expirations.